The U.S. Food and Drug Administration (FDA) has given the green light to Iaso Bio to start clinical testing of its BCMA CAR T-cell therapy equecabtagene autoleucel, known as Eque-cel for short, in people with generalized myasthenia gravis (gMG) who live in the U.S. Clearance of the company’s request,…
A single dose of IASO Bio’s experimental BCMA CAR T-cell therapy equecabtagene autoleucel (CT103A) led to sustained physical function gains in two people with hard-to-treat myasthenia gravis (MG), a recent study suggests. “In our study, it is gratifying to see that BCMA CAR-T cell therapy can prevent MG…
An under-the-skin, or subcutaneous, injectable formulation of efgartigimod alfa has been approved in the U.K. as an add-on therapy for adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor (AChR). This new formulation will be marketed in the U.K. as Subcutaneous Vyvgart. In…
Nipocalimab, an investigational therapy for people with generalized myasthenia gravis (gMG), significantly eased disease severity compared with a placebo, according to top-line data from a pivotal Phase 3 clinical trial. Johnson & Johnson, the therapy’s developer, also plans to engage with regulatory authorities worldwide to present…
Zilbrysq (zilucoplan), a new treatment for adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor (AChR), is now commercially available in the U.S., with a list price likely to exceed $30,000 for a 30-day supply. Approved by the U.S. Food and…
Three microRNAs (miRNAs) — small strands of RNA that regulate protein production — in blood samples accurately identified people with early-onset ocular myasthenia gravis (OMG) and distinguished them from early-onset generalized myasthenia gravis (gMG) patients and healthy people in a recent study. “These results suggested that the three…
Among caregivers of people with myasthenia gravis (MG) living in Northwest China, care burden rises with disease severity and the degree of the patient’s depression, a study reported. According to its researchers, this is primarily driven by patients’ inability to participate more fully in household chores, and the increasing…
Kyverna Therapeutics’ investigational cell therapy KYV-101 safely and effectively improved muscle strength and reduced fatigue in a woman with severe, hard-to-treat generalized myasthenia gravis (gMG), according to a case report. The patient was treated based on an individual case evaluation and outside of a clinical trial. “This groundbreaking…
Recipharm is partnering with Ahead Therapeutics to develop a new type of therapy to reestablish immune tolerance and prevent the self-reactive immune attacks that cause myasthenia gravis (MG). “Together with our partner, we are determined to help them turn hope into reality for people living with myasthenia…
A thymectomy, or surgical removal of the thymus gland, was effective for children and adolescents with myasthenia gravis (MG), as indicated by lower medication use and healthcare utilization after surgery, a study reports. Demographic characteristics like age, sex, ethnicity, insurance payer type, residential region, and the surgical approach…
Get regular updates to your inbox.